We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

Samantha Zottnick, PhD

PhD Student, then Postdoctoral Scientist

Scientific CV

Since Aug 2022
Postdoctoral scientist, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2017 - 2022
PhD student, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2014 - 2017
MSc Biology, Major ‘Molecular Cell Biology & Immunology’, University of Tübingen

Apr 2016 - Oct 2016
Master’s thesis at the Cancer Science Unit, Southampton, UK

2011 - 2014
BSc Biology, University of Tübingen

Research Project

Analysis of factors that facilitate trafficking of vaccination-induced T cells to tumor sites

Human papillomaviruses can cause different malignancies, such as anogenital as well as head and neck cancer. In the search for a therapeutic HPV vaccine, promising preclinical data often fail to translate to a clinical setting. One of the major hurdles of therapeutic vaccination is to target the induced antigen-specific T cells to the tumor site. This is in part due to complex tissue-specific homing signals that T cells need to receive and recognize in order to migrate to the tumor site, and in part to the immunosuppressive tumor microenvironment. In this project, an orthotopic HPV16 tumor model in the genital mucosa has been established in a mouse model expressing human MHC classes I and II. This model will be used to examine how vaccination-induced, HPV16-specific T cells can be attracted to the tumor site. Possibilities include mucosal vaccination routes, irradiation or application of immunomodulatory substances.

Resulting Publications

Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice.
Schifflers C, Zottnick S, Förster JD, Kruse S, Yang R, Wiethoff H, Bozza M, Hoppe-Seyler K, Heikenwälder M, Harbottle RP, Michiels C, Riemer AB. *Equal contributors.
Pathogens. 2023; 12(2):188.

Inducing immunity where it matters: orthotopic HPV tumor models and therapeutic vaccinations.
Zottnick S, Voß AL, Riemer AB.
Frontiers in Immunology 2020, 11: 1750.

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model.
Kruse S, Büchler M, Uhl P, Sauter M, Scherer P, Lan TCT, Zottnick S, Klevenz A, Yang R, Rösl F, Mier W, Riemer AB.
OncoImmunology 2018, 8(1): e1524694.